3-fluoro-4-hydroxythiophenol | 1025925-13-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯硫酚类
• 英文名称: 3-fluoro-4-hydroxythiophenol
• 英文别名: 2-Fluoro-4-mercaptophenol；2-fluoro-4-sulfanylphenol
• CAS: 1025925-13-6
• 化学式: C₆H₅FOS
• 分子量: 144.17
• InChiKey: NELRAYNVCFCGMD-UHFFFAOYSA-N

物化性质

• 沸点：
  232.7±25.0 °C(Predicted)
• 密度：
  1.377±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  21.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-fluoro-4-hydroxythiophenol 在 溴 、 potassium carbonate 作用下， 以 甲醇 、 丙酮 为溶剂， 反应 3.83h， 生成 2-bromo-4-<2-(4-chlorophenylsulfonylamino)ethylthio>-2-fluorophenol
  参考文献：
  名称：

  Synthesis and evaluation of novel fluorinated sulotroban-related sulfonamide derivatives as thromboxane A2 receptor antagonists

  摘要：

  A series of sulotroban-related arylsulfonamide derivatives possessing a fluorinated phenoxyacetic acid moiety was synthesized and tested for TXA(2) antagonizing ability on U-46619-induced platelet aggregation of rabbit platelet-rich plasma. Introduction of one or more fluorine atoms to the phenoxyacetic acid moiety increased this activity. The most potent compound among these compounds was 10c, which was 40-fold more potent (IC50 3.4 x 10(-7) M) than sulotroban. 10c exhibited high activity (ID50, 0.14 mg/kg) against a U-46619-induced acute thrombocytopenia model in mice when orally administrated. These findings and those of radioligand binding assays with various ligands showed 10c to be a potent and selective systemic TXA, receptor antagonist.

  DOI：

  10.1016/0223-5234(96)88250-x
• 作为产物：
  描述：

  2-氟苯酚 在 氯磺酸 、 硫酸 、 锌 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 3-fluoro-4-hydroxythiophenol
  参考文献：
  名称：

  Synthesis and evaluation of novel fluorinated sulotroban-related sulfonamide derivatives as thromboxane A2 receptor antagonists

  摘要：

  A series of sulotroban-related arylsulfonamide derivatives possessing a fluorinated phenoxyacetic acid moiety was synthesized and tested for TXA(2) antagonizing ability on U-46619-induced platelet aggregation of rabbit platelet-rich plasma. Introduction of one or more fluorine atoms to the phenoxyacetic acid moiety increased this activity. The most potent compound among these compounds was 10c, which was 40-fold more potent (IC50 3.4 x 10(-7) M) than sulotroban. 10c exhibited high activity (ID50, 0.14 mg/kg) against a U-46619-induced acute thrombocytopenia model in mice when orally administrated. These findings and those of radioligand binding assays with various ligands showed 10c to be a potent and selective systemic TXA, receptor antagonist.

  DOI：

  10.1016/0223-5234(96)88250-x

文献信息

• BISARYL COMPOUND AND MEDICAMENT FOR CANCER TREATMENT COMPRISING THE SAME
  申请人：——

  公开号：US20030018070A1

  公开（公告）日：2003-01-23

  A medicament for treatment of cancer comprising a compound represented by the following general formula (I) or a physiologically acceptable salt thereof: Ar 1 —S—R 1 —S—Ar 2 wherein R 1 represents a nonmetal bridging group; Ar 1 and Ar 2 independently represent a group selected from the group consisting of an aryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group and said aryl group may have one to three substituents other than hydroxyl group on its ring; and a heteroaryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group, and said heteroaryl group may have one to three substituents other than hydroxyl group on its ring.

  一种治疗癌症的药物，包括以下通用公式（I）所代表的化合物或其生理上可接受的盐：Ar1—S—R1—S—Ar2其中R1代表非金属桥接基团；Ar1和Ar2独立地代表从芳基组中选择的一种组，该芳基组在其环上具有一个至三个羟基，可选地被一价基团取代，并且该芳基组在其环上可能有一个至三个除羟基外的取代基；以及在其环上具有一个至三个羟基的杂环芳基组，可选地被一价基团取代，并且该杂环芳基组在其环上可能有一个至三个除羟基外的取代基。
• Bisaryl compound and medicament for cancer treatment comprising the same
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：US20030199560A1

  公开（公告）日：2003-10-23

  A medicament for treatment of cancer comprising a compound represented by the following general formula (I) or a physiologically acceptable salt thereof: Ar 1 —S—R 1 —S—Ar 2 wherein R 1 represents a nonmetal bridging group; Ar 1 and Ar 2 independently represent a group selected from the group consisting of an aryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group and said aryl group may have one to three substituents other than hydroxyl group on its ring; and a heteroaryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group, and said heteroaryl group may have one to three substituents other than hydroxyl group on its ring.

  一种用于治疗癌症的药物，包含下述一般式（I）所表示的化合物或其生理上可接受的盐：Ar1—S—R1—S—Ar2其中，R1表示非金属桥接基团；Ar1和Ar2独立表示从以下组成的群体中选择的一种群体：在其环上具有一到三个羟基的芳基基团，该芳基基团可以选择性地被单价基团取代，并且该芳基基团的环上可能有一到三个除羟基外的取代基；以及在其环上具有一到三个羟基的杂环基团，该杂环基团可以选择性地被单价基团取代，并且该杂环基团的环上可能有一到三个除羟基外的取代基。
• BISARYL COMPOUNDS AND CANCER REMEDIES CONTAINING THE SAME
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP0990439A1

  公开（公告）日：2000-04-05

  A medicament for treatment of cancer comprising a compound represented by the following general formula (I) or a physiologically acceptable salt thereof:         Ar1-S-R1-S-Ar2 wherein R1 represents a nonmetal bridging group; Ar1 and Ar2 independently represent a group selected from the group consisting of an aryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group and said aryl group may have one to three substituents other than hydroxyl group on its ring; and a heteroaryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group, and said heteroaryl group may have one to three substituents other than hydroxyl group on its ring.

  一种治疗癌症的药物，由以下通式 (I) 所代表的化合物或其生理上可接受的盐组成： Ar1-S-R1-S-Ar2 其中 R1 代表非金属桥基；Ar1 和 Ar2 独立地代表选自以下组别的一个基团：芳基，其环上有一至三个羟基，任选被一价基团取代，且所述芳基环上可有一至三个羟基以外的取代基；杂芳基，其环上有一至三个羟基，任选被一价基团取代，且所述杂芳基环上可有一至三个羟基以外的取代基。
• PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH AMPA RECEPTORS
  申请人：Public University Corporation Yokohama City University

  公开号：EP3569229A1

  公开（公告）日：2019-11-20

  This prophylactic and/or therapeutic agent for diseases associated with AMPA receptors contains a compound represented by formula (I), or a pharmaceutically acceptable salt or solvate thereof. (In the formula, A and Z independently represent CO, SO or SO2; X and Y are independently S or O; R1-R4 are independently hydrogen, an alkyl group, an alkenyl group, an alkynyl group or a halo group; R5 is, independently for each occurrence, an alkyl group, an alkenyl group, an alkynyl group or a halo group; and n is an integer of 0-4).

  这种与 AMPA 受体相关疾病的预防和/或治疗剂含有由式 (I) 代表的化合物或其药学上可接受的盐或溶液。(式中，A 和 Z 独立地代表 CO、SO 或 SO2；X 和 Y 独立地为 S 或 O；R1-R4 独立地为氢、烷基、烯基、炔基或卤代基团；R5 在每次出现时独立地为烷基、烯基、炔基或卤代基团；n 为 0-4 的整数）。
• US6608061B2
  申请人：——

  公开号：US6608061B2

  公开（公告）日：2003-08-19